打开APP

Theraclone治疗流感单克隆抗体研究项目未能获得政府经费支持

  1. NIH
  2. Theraclone
  3. 流感单克隆抗体

来源:生物谷 2013-12-03 10:00

2013年12月2日讯 /生物谷BIOON/ --Theraclone Sciences此前希望政府支持其研究用于对抗流感的单克隆抗体TCN-032,然而最近美国政府下属的美国生物医药高级研究开发局(The Biomedical Advanced Research and Development Authority BARDA)正式拒绝了这一请求,这一决定也迫使Theraclone Sciences靠自身努力来进行这一项目的二期临床研究。不过公司CEO Clifford Stocks并未放弃,他表示已经计划与BARDA官员会面并讨论下一步计划。

Clifford Stocks表示尽管这一项目未能获得BARDA资助,公司仍然看重TCN-032在预防流感的重要性和其商业化潜力。目前除了这一项目,公司还有一项旨在治疗器官移植患者巨细胞病毒感染的单克隆抗体项目TCN-202处于临床研究中。这两项计划都是依托于公司的I-STAR discovery platform进行的。

在今年8月份,公司和PharmAthene公司签署合并协议,以将公司的抗体技术拓展到疫苗领域,不过这一合并计划还在股东审核当中。(生物谷Bioon.com)

详细英文报道:

Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.

The Biomedical Advanced Research and Development Authority has opted against bankrolling Theraclone's TCN-032, a human monoclonal antibody designed to fight the flu. That leaves the biotech to its own devices in advancing the Phase II-ready therapy, but CEO Clifford Stocks said he hasn't given up, planning to meet with BARDA to flesh out a future proposal.

"While we are disappointed that we did not receive BARDA funding at this time, we remain encouraged by the potential of TCN-032 for two current indications--to help combat pandemic flu as well as the commercial potential to treat patients who are hospitalized with serious influenza infections given the novel mechanism, mutation resistance and extended therapeutic window of our antibody to flu," Stocks said in a statement.

Theraclone, a 2011 Fierce 15 member, is also in the midst of a Phase IIa trial for TCN-202, a monoclonal antibody designed to prevent human cytomegalovirus infection in patients undergoing organ transplants. Both treatments stem from the company's I-STAR discovery platform, designed to identify rare human antibodies that can be whipped up into effective drugs.

In August, Theraclone signed a deal to merge with biodefense drug developer PharmAthene ($PIP) in an all-stock deal, looking to marry its antibody programs with some promising biochemical vaccines. The agreement is still pending shareholder approval.

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->